Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

from Entrepreneur https://ift.tt/3o9qBgh
via IFTTT